



Home / Research and development / Therapy areas of research / Inhaled medicinal products - the Easyhaler® platform


## Inhaled medicinal products - the Easyhaler® platform

The Easyhaler®, a device-metered dry powder Inhaler developed and patented by Orion, is an environmentally friendly and efficient, yet easy to use inhaler for the treatment of respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD). Orion aims to expand the product family of inhalable Easyhaler® drugs used for treating asthma and chronic obstructive pulmonary disease. Easyhaler products are available in more than 25 countries worldwide.

Currently four medicinal products are available in the patient-friendly Easyhaler® device.

Medicinal product	Active substance	Use
Budesonid Easyhaler®	Budesonide	Controller medication for asthma.
Beclomet Easyhaler®	Beclometasone	Controller medication for asthma.
Formoterol Easyhaler®	Formoterol	Controller medication for combination treatment of asthma and bronchodilator for maintenance treatment of COPD.
Buventol Easyhaler®	Salbutamol (albuterol)	Reliever medication for asthma and COPD; protector against bronchoconstrictors.

A dry powder inhaler delivers the active drug substance directly to the lower airways, where it exerts its intended effect. Only small amounts of active substance become available in the circulating blood, keeping any unintended harmful effects to a minimum. This guarantees a maximal benefit-to-risk ratio for inhaled treatments.



New medicinal products utilizing the Easyhaler technology platform are under development.

Orion is developing known active substances and their combinations for use in the Easyhaler and there are clinical studies on-going.

In addition, the Easyhaler platform can be used in the research and development of new molecular entities and proprietary products. In the future it is possible to develop dry powder formulations for inhalation of drugs used in the systemic treatment of illnesses outside the respiratory tract.

Orion has ongoing projects to broaden the range of the inhalable *Easyhaler® drugs* product family. Orion submitted an application for marketing authorisation for a combined *budesonide-formoterol formulation* in Europe in March, and the application is being processed. In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator.

In addition, Orion has another Easyhaler research programme in progress to develop a combined *fluticasone-salmeterol formulation* for European markets. In this formulation fluticasone acts as an anti-inflammatory agent and salmeterol acts as a long-acting bronchodilator.

Updated Oct 30th 2013

Orion Corporation, Orionintie 1A, 02200 Espoo, PO Box 65, FI-02101 Espoo, Finland  
Phone +358 104261 © Copyright Orion Corporation. Company code, VAT 19992126,